Suppr超能文献

甲状腺微小乳头状癌和直径≤1cm的甲状腺乳头状癌:世界卫生组织的修订定义及治疗困境

Papillary microcarcinoma and papillary cancer of the thyroid <or=1 cm: modified definition of the WHO and the therapeutic dilemma.

作者信息

Schönberger J, Marienhagen J, Agha A, Rozeboom S, Bachmeier E, Schlitt H, Eilles C

机构信息

Department of Nuclear Medicine, University of Regensburg, 93042 Regensburg, Germany.

出版信息

Nuklearmedizin. 2007;46(4):115-20; quiz N41-2.

Abstract

AIMS

Major controversies exist regarding the treatment of papillary microcarcinoma of the thyroid (PMC). Prior to 2003 PMC was defined by the WHO as a papillary carcinoma of 1 cm or less in diameter. In 2004 that definition changed, with the new classification requiring that the tumour also must be found incidentally.

PATIENTS, METHODS: In this study we reviewed the clinical records of 67 patients with papillary tumours of the thyroid <or=1 cm, taking into account the new WHO definition (54 pts. with incidentally found PMC, median age: 53 years, 13 pts. with suspicion of thyroid neoplasm before resection, median age: 38 years). Clinical presentation, surgical treatment, further therapy and follow-up are presented.

RESULTS

Median tumour size was 7 mm in both groups (1-10 mm). Multicentric tumours were found in 15 pts. (22%), 8 had more than one PMC on the same side, and 7 displayed PMC bilaterally. Eleven (16%) of the primary tumors had metastatic involvement of regional lymph nodes at the time of initial surgery or during follow-up. Two patients showed distant metastases. No correlation between tumour size and multifocality or the presence of lymph node metastases could be seen. The gender of patients was the only significant independent variable for all patients; age and lymph node involvement was significantly different between incidentally and non-incidentally found PMC.

CONCLUSIONS

Despite the majority of patients with PMC having an excellent outcome, there are also cases showing an unfavorable course. Currently no predictive parameter exists to anticipate the course and long-term outcome for an individual patient. Until this problem is solved, each patient should have the option to decide for him or herself whether to be treated similarly or differently than for conventional thyroid cancer.

摘要

目的

甲状腺微小乳头状癌(PMC)的治疗存在重大争议。2003年之前,WHO将PMC定义为直径1厘米或更小的乳头状癌。2004年该定义发生了变化,新分类要求肿瘤还必须是偶然发现的。

患者、方法:在本研究中,我们回顾了67例甲状腺乳头状肿瘤≤1厘米患者的临床记录,考虑了WHO的新定义(54例偶然发现的PMC患者,中位年龄:53岁,13例术前怀疑甲状腺肿瘤患者,中位年龄:38岁)。介绍了临床表现、手术治疗、进一步治疗及随访情况。

结果

两组患者肿瘤中位大小均为7毫米(1 - 10毫米)。15例(22%)发现多中心肿瘤,8例在同一侧有不止一个PMC,7例双侧有PMC。11例(16%)原发性肿瘤在初次手术时或随访期间出现区域淋巴结转移。2例患者出现远处转移。未发现肿瘤大小与多中心性或淋巴结转移之间存在相关性。患者性别是所有患者唯一显著的独立变量;偶然发现和非偶然发现的PMC患者在年龄和淋巴结受累方面存在显著差异。

结论

尽管大多数PMC患者预后良好,但也有一些病例显示出不良病程。目前不存在预测个体患者病程和长期预后的参数。在这个问题解决之前,每个患者都应该有选择决定自己接受与传统甲状腺癌相同或不同治疗的权利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验